Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 1.45
Ask: 1.55
Change: 0.00 (0.00%)
Spread: 0.10 (6.897%)
Open: 1.50
High: 1.50
Low: 1.475
Prev. Close: 1.50
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genedrive test to go through new, faster NICE process

Mon, 26th Sep 2022 14:10

(Sharecast News) - Molecular diagnostics technology company Genedrive announced on Monday that the UK's National Institute for Health and Clinical Excellence (NICE) has transferred the evaluation of its 'MT-RNR1' test to a new 'early value assessment programme'.

The AIM-traded firm said the programme is a new review process, created to drive innovation into the hands of healthcare professionals by actively drawing in digital products, medical devices and diagnostics that address national unmet needs.

It said the programme would allow the NICE diagnostics advisory committee to consider the technology "much faster", resulting in a published report in a six month timeframe instead of the initial 63 weeks - approximately 14 months - via the diagnostics assessment programme.

A provisional schedule was published by NICE, indicating the consultation process would occur in February.

Genedrive described the MT-RNR1 assay as "the world's first" rapid point-of-care test to screen infants in an urgent care setting for a genetic variant that would cause life-long hearing loss when carriers of the variant were given certain antibiotics.

Those that carry the variant could then be given alternative treatments following detection of the variant by the Genedrive test.

"We are grateful to NICE for their engagement and interest in our innovative technology and pleased that the Genedrive MT-RNR1 test has been fast tracked via their new EVA programme, which may allow clinicians and patients to benefit from the test sooner," said chief executive officer David Budd.

"This is a testament to our technology and our ability to address this unmet need."

At 1309 BST, shares in Genedrive were up 2.13% at 12p.

Reporting by Josh White at Sharecast.com.

More News
19 Apr 2021 14:10

UPDATE: Yourgene wins further national framework contract award

UPDATE: Yourgene wins further national framework contract award

Read more
19 Apr 2021 12:46

IN BRIEF: Genedrive included in Public Health England framework

IN BRIEF: Genedrive included in Public Health England framework

Read more
19 Apr 2021 12:07

Genedrive appointed to PHE microbiology supply framework

(Sharecast News) - Molecular diagnostics company Genedrive has been successful with its tender to Public Health England (PHE) under Lot 1 of the National Microbiology Framework for diagnostic goods and services, it announced on Monday.

Read more
19 Apr 2021 11:44

Yourgene wins national contract award for Covid-19 testing services

Yourgene wins national contract award for Covid-19 testing services

Read more
19 Apr 2021 11:32

AIM WINNERS & LOSERS: Pantheon falls after Alaska drilling results

AIM WINNERS & LOSERS: Pantheon falls after Alaska drilling results

Read more
25 Mar 2021 14:49

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

Read more
25 Mar 2021 11:28

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

Read more
18 Mar 2021 16:06

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
9 Mar 2021 14:34

IN BRIEF: Genedrive to distribute pathogen detection assays in US

IN BRIEF: Genedrive to distribute pathogen detection assays in US

Read more
3 Mar 2021 21:53

TRADING UPDATES: Team PLC prices IPO; Nostra's Cypress doubles

TRADING UPDATES: Team PLC prices IPO; Nostra's Cypress doubles

Read more
17 Feb 2021 11:27

AIM WINNERS & LOSERS: Blockchain Stocks Rise As Bitcoin Hits New High

AIM WINNERS & LOSERS: Blockchain Stocks Rise As Bitcoin Hits New High

Read more
17 Feb 2021 09:32

Genedrive Makes First Shipments Of SARS-CoV-2 Test Kits To US

Genedrive Makes First Shipments Of SARS-CoV-2 Test Kits To US

Read more
28 Jan 2021 14:26

IN BRIEF: Genedrive Soars After Sealing PCR Test Distribution Deal

IN BRIEF: Genedrive Soars After Sealing PCR Test Distribution Deal

Read more
28 Jan 2021 10:22

AIM WINNERS & LOSERS: Eurasia Rallies As It Explains Churakov Sale

AIM WINNERS & LOSERS: Eurasia Rallies As It Explains Churakov Sale

Read more
21 Dec 2020 18:10

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.